Nicotinamide adenine dinucleotide (NAD+) is a coenzyme found in every living cell that has become one of the most heavily studied molecules in longevity research. NAD+ sits at the intersection of metabolism, DNA repair, and aging biology — making it a subject of interest across multiple research disciplines. This review summarizes the published literature on NAD+, the biological pathways researchers have examined, and what the aging research has established about NAD+ levels over time.
NAD+ is a dinucleotide functioning as an electron carrier in cellular respiration and as a substrate for several enzyme classes linked to aging biology. The primary enzymatic families that consume NAD+ and have attracted the most research interest are sirtuins and poly ADP-ribose polymerases (PARPs). Published research by Massudi et al. (2012) documented a progressive decline in NAD+ metabolite levels in human tissue samples beginning in middle age — a finding cited extensively as rationale for studying NAD+ supplementation effects.
Massudi H, et al. Age-associated changes in oxidative stress and NAD+ metabolism in human tissue. PLoS One. 2012;7(7):e42357.
Sirtuins are a family of seven NAD+-dependent protein deacetylases (SIRT1–SIRT7) studied extensively in the context of aging, metabolic regulation, and cellular stress responses. Because sirtuins require NAD+ as a co-substrate — consuming it during deacylation reactions — researchers have hypothesized that declining NAD+ levels with age may limit sirtuin activity. Work from Dr. David Sinclair’s laboratory at Harvard and Dr. Leonard Guarente’s laboratory at MIT has examined SIRT1 and SIRT3 activity in the context of NAD+ availability and mitochondrial function, generating substantial follow-on research.
Guarente L. Sirtuins, aging, and metabolism. Cold Spring Harb Symp Quant Biol. 2011;76:81–90.
Poly ADP-ribose polymerases (PARPs) are enzymes that use NAD+ to synthesize poly(ADP-ribose) chains in response to DNA strand breaks — a fundamental mechanism in single-strand DNA damage repair. Because PARP activity consumes NAD+, researchers have examined whether increased DNA damage burden associated with aging creates competition between PARP-mediated repair and sirtuin-mediated metabolic regulation for available NAD+. Published research by Bai et al. demonstrated that PARP1 inhibition in aged mice increased NAD+ availability and was associated with improved mitochondrial function — findings attributed to restored sirtuin activity.
Because NAD+ itself has limited cellular uptake due to its molecular size and charge, researchers have focused on precursor compounds — primarily nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — as well as direct NAD+ supplementation. A 2018 Phase 1 human clinical study by Martens et al. (Cell Metabolism) reported that NR supplementation raised NAD+ metabolite levels in peripheral blood mononuclear cells in healthy middle-aged and older adults. Researchers have noted that translation from blood NAD+ levels to tissue-specific effects remains an active area of investigation.
NAD+ is a critical electron carrier in the mitochondrial electron transport chain, serving as substrate for Complex I (NADH dehydrogenase). Research examining mitochondrial function in aged cells has documented alterations in the NAD+/NADH ratio, which researchers have associated with impaired ATP production and increased reactive oxygen species — both features of mitochondrial aging well-documented in the published literature.
For informational purposes only. NAD+ 500mg is available through Brava Longevity as a research compound. This is not medical advice or dosing guidance.
